CNS target could lead to development of drugs for diabetes
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP…
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.